Table 2.
Clinical demographic characteristics of patients with and without febrile neutropenia in the testing dataset.
| Parameters | FN group (n = 43) | non-FN group (n = 47) | p value |
|---|---|---|---|
| Age (years), means ± SD | 0.050 | ||
| ≤ 50 | 13 (30.2) | 24 (51.1) | |
| > 50 | 30 (69.8) | 23 (48.9) | |
| Body surface area (m2), means ± SD | 1.61 ± 0.14 | 1.63 ± 0.14 | 0.383 |
| Hypertension, n (%) | 12 (27.9) | 11 (23.4) | 0.638 |
| Diabetes mellitus, n (%) | 5 (11.6) | 5 (10.6) | 1.000 |
| Tuberculosis, n (%) | 0 (0) | 0 (0) | 1.000 |
| Breast-conserving surgery, n (%) | 28 (65.1) | 37 (78.7) | 0.166 |
| Tumor size (cm), mean ± SD | 2.7 ± 1.3 | 2.5 ± 1.2 | 0.490 |
| Positive lymph node, means ± SD | 1.7 ± 4.0 | 0.3 ± 1.4 | 0.038 |
| ER, n (%) | 34 (79.1) | 26 (55.3) | 0.046 |
| PR, n (%) | 26 (60.5) | 18 (38.3) | 0.057 |
| Her-2, n (%) | 12 (27.9) | 7 (14.9) | 0.196 |
| CA 15–3, means ± SD | 15.2 ± 12.0 | 11.7 ± 7.8 | 0.140 |
| TNM staging, n (%) | 0.003 | ||
| I/II | 33 (76.7) | 46 (97.9) | |
| III/IV | 10 (23.3) | 1 (2.1) | |
| Taxane-based regimen, n (%) | 23 (53.5) | 14 (29.8) | 0.032 |
| CBC (before chemotherapy), means ± SD | |||
| Hemoglobin (g/dL) | 13.0 ± 1.6 | 13.1 ± 1.2 | 0.940 |
| Platelet (× 103/µL) | 263 ± 56 | 265 ± 77 | 0.590 |
| Neutrophil (× 103/µL) | 3.661 ± 1.574 | 4.006 ± 1.683 | 0.550 |
| Lymphocyte (× 103/µL) | 2.024 ± 0.575 | 2.193 ± 0.640 | 0.250 |
| CBC (5 days after chemotherapy), means ± SD | |||
| Hemoglobin (g/dL) | 10.7 ± 1.1 | 5.314 ± 1.593 | 0.017 |
| Platelet (× 103/µL) | 219 ± 99 | 11.3 ± 1.0 | 0.170 |
| Neutrophil (× 103/µL) | 3.977 ± 3.468 | 3.348 ± 1.208 | 0.220 |
| Lymphocyte (× 103/µL) | 0.838 ± 0.339 | 1.703 ± 0.683 | < 0.001 |
| SERM, n (%) | 13 (30.2) | 23 (48.9) | 0.087 |
| LHRH, n (%) | 11 (25.6) | 20 (42.6) | 0.121 |
| Aromatase inhibitor, n (%) | 22 (51.2) | 14 (29.8) | 0.053 |
| Radiation treatment, n (%) | 35 (81.4) | 41 (87.2) | 0.564 |
| Herceptin, n (%) | 13 (30.2) | 10 (21.3) | 0.346 |
FN febrile neutropenia, SD standard deviation, ER estrogen receptor, PR progesterone receptor, Her-2 human epidermal growth factor receptor 2, CA cancer antigen, CBC complete blood count, SERM selective estrogen receptor modulator, AI aromatase inhibitor, LHRH luteinizing hormone-releasing hormone, F/U follow-up.